Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Janero

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Expert Opinion on Emerging Drugs|February 17, 2012
Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonistsDavid R Janero
Expert Opinion on Drug Discovery|December 13, 2012
Developing doctoral scientists for drug discovery: pluridimensional education requiredDavid R Janero
Expert Opinion on Drug Discovery|June 27, 2014
The future of drug discovery: enabling technologies for enhancing lead characterization and profiling therapeutic potentialDavid R Janero
Expert Opinion on Drug Discovery|August 28, 2014
Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioningDavid R Janero
Expert Opinion on Pharmacotherapy|October 26, 2013
Relieving the cardiometabolic disease burden: a perspective on phytometabolite functional and chemical annotation for diabetes managementDavid R Janero
Expert Opinion on Drug Discovery|January 9, 2014
Synthetic agents in the context of metabolic/bariatric surgery: expanding the scope and impact of diabetes drug discoveryDavid R Janero
Expert Opinion on Drug Discovery|May 1, 2012
Productive university, industry, and government relationships in preclinical drug discovery and development: considerations toward a synergistic lingua francaDavid R Janero
Expert Opinion on Drug Discovery|July 13, 2016
The reproducibility issue and preclinical academic drug discovery: educational and institutional initiatives fostering translation successDavid R Janero
Expert Opinion on Drug Discovery|November 8, 2023
Current strategic trends in drug discovery: the present as prologueDavid R Janero
Expert Opinion on Emerging Drugs|March 3, 2009
Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosisDavid R Janero, Alexandros Makriyannis
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Expert Opinion on Emerging Drugs|February 17, 2012
Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonistsDavid R Janero
Expert Opinion on Drug Discovery|December 13, 2012
Developing doctoral scientists for drug discovery: pluridimensional education requiredDavid R Janero
Expert Opinion on Drug Discovery|June 27, 2014
The future of drug discovery: enabling technologies for enhancing lead characterization and profiling therapeutic potentialDavid R Janero
Expert Opinion on Drug Discovery|August 28, 2014
Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioningDavid R Janero
Expert Opinion on Pharmacotherapy|October 26, 2013
Relieving the cardiometabolic disease burden: a perspective on phytometabolite functional and chemical annotation for diabetes managementDavid R Janero
Expert Opinion on Drug Discovery|January 9, 2014
Synthetic agents in the context of metabolic/bariatric surgery: expanding the scope and impact of diabetes drug discoveryDavid R Janero
Expert Opinion on Drug Discovery|May 1, 2012
Productive university, industry, and government relationships in preclinical drug discovery and development: considerations toward a synergistic lingua francaDavid R Janero
Expert Opinion on Drug Discovery|July 13, 2016
The reproducibility issue and preclinical academic drug discovery: educational and institutional initiatives fostering translation successDavid R Janero
Expert Opinion on Drug Discovery|November 8, 2023
Current strategic trends in drug discovery: the present as prologueDavid R Janero
Expert Opinion on Emerging Drugs|March 3, 2009
Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosisDavid R Janero, Alexandros Makriyannis
Pageof 7